OGP-AcAP5 fusion protein for treating osteoporosis and thrombosis and nucleic acid for coding same
A technology for osteoporosis and fusion protein, applied in the field of fusion protein and nucleic acid encoding the fusion protein, can solve the problems of patient inconvenience, antagonistic reaction, etc., and achieve the effect of safe use
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
specific Embodiment approach 1
[0012] Specific embodiment 1: The amino acid sequence of the OGP-AcAP5 fusion protein used for treating osteoporosis and thrombus in this embodiment is shown in SEQ ID NO:2.
[0013] The nucleic acid sequence of the OGP-AcAP5 fusion protein used in the treatment of osteoporosis and thrombosis in this embodiment is shown in SEQ ID NO: 1. The nucleic acid sequence was synthesized by a bioengineering company to make a plasmid vector pUC( OGP / AcAP5). The pUC (OGP / AcAP5) vector was double-digested with BamHI and EcoR I (the enzyme digestion system is shown in Table 1), and pGEX-6P-1 was double-digested with BamHI and EcoR I (the enzyme digestion system was shown in Table 1). 2); then the present embodiment is used for the connection of the DAN fragment (OGP / AcAP5) of the OGP-AcAP5 fusion protein (OGP / AcAP5) for the treatment of osteoporosis and thrombus with the carrier pGEX-6P-1 through double digestion (ligation reaction system as shown in Table 3).
[0014] Table 1
[0015] ...
specific Embodiment approach 2
[0058] Embodiment 2: The nucleic acid sequence of the OGP-AcAP5 fusion protein used in the treatment of osteoporosis and thrombus in this embodiment is shown in SEQ ID NO:1.
[0059] The nucleic acid sequence of the OGP-AcAP5 fusion protein used in the treatment of osteoporosis and thrombus in this embodiment was synthesized by a bioengineering company.
[0060] In this embodiment, the original signal peptide of the AcAP5 gene is removed from the nucleic acid sequence of the OGP-AcAP5 fusion protein used to treat osteoporosis and thrombosis, and a Kpn I restriction enzyme is inserted between the osteogenic growth peptide and the anticoagulant peptide of H. caninum The site can not only improve the stability of the encoded fusion protein, but also change the secondary structure of the fusion protein to improve its biological performance.
[0061] In this embodiment, BamHI and EcoR I restriction sites are respectively added on both sides of the fusion protein gene, and the codin...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 